Europe Unlicensed Specials Manufacturing Routes and Access Pathways

Why Route to Market Defines an Unlicensed Special

An unlicensed special is defined by how it reaches the patient. The same active ingredient can be a licensed product in one market, a specially made liquid in another and an import in a third, and that is why route to market is the organising idea of the Europe unlicensed specials market.

The full report uses two related dimensions. The first is manufacturing route, which describes how the product is physically sourced: special manufacturing, reformulated medicines, imported unlicensed medicines and named patient imports. The second is regulatory route, which describes the access category under which it is supplied: MHRA specials, the EMA framework, named patient supply, compassionate use and hospital exemptions.

The two dimensions are connected but not identical. A named patient import is both a way of sourcing a product and an access category, while special manufacturing may sit inside the MHRA specials category in the United Kingdom and under national arrangements elsewhere in Europe. Mapping one onto the other is one of the analytical tasks of the full report.

For buyers, route decides lead time, documentation, the number of intermediaries and the confidence that a repeat order will be filled on the same terms. For suppliers, route decides which capabilities must be held in house, which partners are needed and which buyers can be reached at all.

Access categories are described here as market labels only and not as statements of what any authority requires.

Because shortages are the commonest trigger for a switch of route, many buyers keep more than one route open for their most important products, and the second half of this page describes how those routes are combined.

Seen from the supplier side, the number of routes a company can credibly offer is a more telling indicator of its position than the number of products it lists, because each route brings its own documentation, logistics and customer service obligations.

Special Manufacturing and Reformulated Medicines

Special manufacturing is the route in which a product is made to order by a manufacturer for a named prescriber or institution. The product may be a new presentation of an active ingredient, such as a liquid, a different strength or a sterile preparation, and it is made against a specific request rather than for general sale.

Reformulated medicines start from an existing licensed product and convert it into a different presentation, for example from a tablet into a liquid. The distinction from special manufacturing is one of starting point: reformulation begins with a finished medicine, whereas special manufacture often begins with raw materials.

In commercial terms both routes depend on formulation capability, stability knowledge and the ability to run small batches efficiently. These are the same capabilities that the report's vendor selection criteria identify as important to buyers, including formulation capabilities, stability studies, manufacturing quality and product availability.

Special manufacturing carries higher unit costs than mass production, because batch sizes are small and changeovers are frequent. This explains why hospital procurement teams pay close attention to framework agreements, and why manufacturers look for ways to improve manufacturing economics through scheduling and portfolio concentration.

It also explains why reformulation is attractive. A manufacturer that can convert a licensed tablet into a stable liquid can often build a recurring product with predictable demand, which is a better commercial position than a series of one-off special requests.

Hospital pharmacies also differ in how much of this work they keep in house. Units with their own preparation facilities may choose special manufacturing only for products that they cannot make themselves, whereas units without such facilities rely on external manufacturers for the whole range, which changes the volume that reaches suppliers.

Imported Unlicensed Medicines and Named Patient Imports

Imported unlicensed medicines are products that are licensed or approved in another country and brought in to meet a need that the domestic licensed range cannot. Where an import is arranged for one identified patient it is called a named patient import, and the two are shown separately in the report because the volumes, buyers and suppliers are different. Imports often depend on the way product types and dosage forms are presented abroad, since a foreign label, pack size or strength changes how readily a buyer can use the product.

Imports are the principal response to shortages and discontinuations. When a licensed domestic product becomes unavailable, an import from another European market may be the fastest source of supply, and import specialists have built businesses around sourcing, documenting and delivering such products.

The commercial characteristics of imports differ from those of manufactured specials. Lead times depend on international logistics, product availability is exposed to events in the source market and documentation burden is higher. Pharmacy teams cite import delays and regulatory complexity among their pain points in the full report.

On the other hand imports require no formulation development by the importer and can cover a wide range of products with a relatively small organisation. This is why import specialists form a distinct group among suppliers, alongside manufacturers and distributors.

Named patient imports add a further layer of administration because each request is tied to an individual, and so the order volume is lower and the service element, including tracking, urgency handling and communication with the clinical team, is a larger part of what the buyer is purchasing.

Quality systems and traceability are an additional factor in reformulated and special products. Buyers look for evidence of batch records, stability data and consistent supply, and these are described in the vendor selection criteria as manufacturing quality, stability studies and delivery reliability, which are market selection factors rather than statements of regulatory requirement.

MHRA Specials and the EMA Framework as Access Categories

MHRA specials and the EMA framework are the two broad regulatory route labels in the source. The first refers to the United Kingdom arrangements under which specially made medicines are supplied, and the second to the framework associated with the European Medicines Agency and its member systems. This report uses them as descriptive labels for market access only.

The significance of the distinction for the market is geographic. UK-focused specialists have built their businesses around the MHRA specials arrangements and around NHS procurement, while manufacturers that wish to supply several European countries must work across more than one national system alongside the EMA framework.

This is a central reason why European expansion appears among the strategic developments in the full report. A UK specialist expanding into Germany or France is not simply adding customers; it is adding a different access pathway, different documentation expectations and a different set of procurement habits.

For multinational specialty pharma companies the position is the reverse. They typically enter the category through products that already hold approvals in several markets, and they rely on their access to the EMA framework to extend those products across borders.

Readers should therefore treat access categories as a dimension of supplier positioning. In the competitive benchmarking section of the full report, regulatory strength and the breadth of geographic coverage are separate measures, which acknowledges that a supplier may be strong nationally without having a European reach.

A related point is that import specialists often act as aggregators, holding relationships with many source manufacturers and presenting a single catalogue to hospital buyers. That aggregation role means they compete with wholesalers as much as with manufacturers, and it explains why distribution partnerships appear frequently among reported strategic developments.

Named Patient Supply, Compassionate Use and Hospital Exemptions

Named patient supply, compassionate use and hospital exemptions are three further access categories. Named patient supply describes provision of a medicine for an identified individual on the request of a clinician. Compassionate use describes provision of a medicine that is not yet generally available to patients with a serious need. Hospital exemptions describe preparation or supply carried out within a hospital setting for its own patients.

In market terms these categories attract different suppliers. Named patient and compassionate use supply is served by import specialists and by manufacturers with access to products not yet widely marketed, and the commercial relationship is built around the channels that move specials to prescribers. Hospital exemptions are largely internal and affect how much work is available to external suppliers.

The relative importance of hospital exemptions is one reason why hospital outsourcing appears as a source of untapped opportunity. Where a hospital preparation unit reaches the limit of its capacity or decides to stop certain preparations, external suppliers are asked to take on the work, and the volume that moves is a function of hospital policy as much as of patient demand.

Compassionate use is smaller in volume but important for specialist clinics, oncology centres and rare disease treatment, where products may be needed before a general supply route exists. Suppliers that can handle such requests reliably build strong relationships with the clinical teams involved.

Across all three categories, the buyer is typically a clinician or a chief pharmacist rather than a procurement department, and the speed and clarity of response matters at least as much as the cost of the product.

One consequence is that the clinical team is often the real customer even where the order is placed by a pharmacy, so suppliers that provide clear information, rapid confirmation of availability and a named contact for urgent requests are typically preferred over suppliers that compete on catalogue breadth alone.

How Routes Combine Within a Single Buyer Relationship

Most large buyers use several routes at once. A hospital pharmacy may take a specially made liquid from one manufacturer, an imported tablet through a wholesaler and a named patient import through an import specialist, all for patients in the same department.

This has consequences for suppliers. A supplier that can offer more than one route, for example manufacturing together with import capability, becomes a more convenient single point of contact, and the report's competitive benchmarking therefore tracks product breadth and distribution capability alongside manufacturing capability.

It also has consequences for continuity. A buyer facing a shortage of a licensed product will normally consider the routes in a predictable order: a reformulated or special product if one exists, an import if it does not, and a named patient arrangement for the most specific cases. Suppliers that anticipate this sequence by holding a portfolio ready can respond faster.

Finally, routes combine over time. Products that begin as named patient imports may move to a regular imported supply as demand grows, and a regular import may be replaced by a specially manufactured product once a manufacturer has developed a stable formulation.

The full report tracks these shifts through strategic developments such as capacity expansions, new oral liquid launches, distribution partnerships and manufacturing investments. Together they show a category in which routes are less fixed than they appear in a static segmentation, and where the relationship with the buyer matters as much as the route itself.

Looking ahead, digital ordering and tracking integration between suppliers and hospital pharmacy systems is one of the areas flagged for untapped opportunity, since it reduces the administration attached to each route and makes the best option easier to identify at the moment of need.